WASHINGTON and CAMBRIDGE, Mass., June 2, 2014 (GLOBE NEWSWIRE) -- REGENX Biosciences, LLC and Voyager Therapeutics today announced that they have entered into a license agreement for use of REGENX’s proprietary NAV® vectors for the development and commercialization of gene therapies to treat Amyotrophic Lateral Sclerosis (ALS), Friedreich’s ataxia (FA) and Huntington’s disease (HD).
Help employers find you! Check out all the jobs and post your resume.
